A new research paper titled "FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet" has been published in Aging.
Mar 20, 2024
0
0
In hepatic steatosis, hepatocytes "die," resulting in liver damage. Severe steatosis increases hepatocellular deaths, thus aggravating liver damage. The mechanism is unclear. Using mice, we show that mild steatosis causes ...
Feb 15, 2023
0
48
(HealthDay)—Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are highly effective for reducing hepatic steatosis in patients with severe obesity and type 2 diabetes, with almost complete clearance of liver fat ...
Nov 30, 2021
0
6
New research has uncovered genetic variations that may contribute to the development of non-alcoholic fatty liver disease (NAFLD), the leading cause of liver disease.
Nov 5, 2018
0
0
Losing a single night's sleep may affect the liver's ability to produce glucose and process insulin, increasing the risk of metabolic diseases such as hepatic steatosis (fatty liver) and type 2 diabetes. The findings of ...
Sep 5, 2018
0
1
Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces ...
Jun 6, 2018
1
612
(HealthDay)—Hepatic fat accumulation may play a causal role in chronic liver disease, according to a study published online Dec. 27 in the Journal of Internal Medicine.
Jan 11, 2018
0
3
Researchers' global estimates indicate that by 2025, some 268 million children aged 5 to 17 years may be overweight, including 91 million obese, assuming no policy interventions have proven effective at changing current trends.
Oct 8, 2016
0
3
Researchers have developed a diagnostic model that is highly predictive of nonalcoholic fatty liver disease (NAFLD). Referred to as the Framingham Steatosis Index (FSI), this novel model may become a cheaper and easier alternative ...
Jul 13, 2016
0
0
(HealthDay)—Inhibition of phosphodiesterase-4 (PDE4), which hydrolyses cyclic adenosine monophosphate (cAMP), may be useful for treating metabolic disorders, according to research published in the May issue of Obesity Reviews.
Apr 12, 2016
0
1
